表紙
市場調査レポート

PharmaPoint:関節リウマチ - インドにおける医薬品の予測と市場分析

PharmaPoint: Rheumatoid Arthritis - India Drug Forecast and Market Analysis to 2023

発行 GlobalData 商品コード 259964
出版日 ページ情報 英文 173 Pages
即納可能
価格
本日の銀行送金レート: 1USD=104.18円で換算しております。
Back to Top
PharmaPoint:関節リウマチ - インドにおける医薬品の予測と市場分析 PharmaPoint: Rheumatoid Arthritis - India Drug Forecast and Market Analysis to 2023
出版日: 2014年12月31日 ページ情報: 英文 173 Pages
概要

当レポートでは、インドの関節リウマチ市場について調査しており、市場の概要、競合情勢、主要薬剤の詳細情報とSWOT分析、主要薬剤の売上予測、主要イベントの影響分析、市場影響因子の分析などをまとめています。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因と病態生理学
    • 病因
    • 病態生理学
  • 症状
  • 予後
  • 生活の質 (QOL)

第4章 疾患の管理

  • 疾患と治療の概要
    • 診断
    • 治療ガイドライン
    • 関節リウマチ治療のための主な処方薬
    • 臨床診療
  • インド

第5章 競合評価

  • 概要
  • 製品プロファイル - 主要ブランド
    • Enbrel (エタネルセプト)
    • Remicade (インフリキシマブ)
    • Orencia (アバタセプト)
    • Actemra/RoActemra (トシリズマブ)
    • Rituxan/MabThera (リツキシマブ)
    • Inflectra/Remsima (インフリキシマブのバイオシミラー)
    • Methotrexate
  • バイオシミラー
    • イントロダクション
    • 主な自己免疫疾患に関するHospiraのInflectraとJ & JのRemicadeの対比
    • 免疫学コミュニティにおけるバイオシミラー
    • 開発中のバイオシミラーの件数
    • 製薬産業全体を通じて感じられるバイオシミラーの影響度
    • 関節リウマチ向けバイオシミラーの普及率は市場によって異なる見通し
  • その他の治療薬

第6章 アンメットニーズと機会

  • 概要
  • コスト効率の高い治療薬の開発
    • アンメットニーズ
    • ギャップ分析
    • 機会
  • 治療への反応度を予測するためのバイオマーカー
    • アンメットニーズ
    • ギャップ分析
    • 機会
  • 関節リウマチの早期診断
    • アンメットニーズ
    • ギャップ分析
    • 機会
  • 個別化治療によるアプローチ
    • アンメットニーズ
    • ギャップ分析
    • 機会

第7章 パイプライン評価

  • 概要
  • 臨床開発における有望な治療薬
    • Sirukumab
    • Cosentyx (secukinumab)
    • Baricitinib
    • RAVAX
  • 開発中のその他の医薬品

第8章 市場の見通し

  • 成長因子と障壁 - 世界における課題
  • インド
    • 予測
    • 主な出来事
    • 成長因子と障壁

第9章 付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC269CFR

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.

The drivers of growth in this market include the increasing RA patient population, and economic growth, which has led to increased investment in the national healthcare system. However, Indian physicians' preference for generics and biosimilars, which have been known to launch prior to patent expiry, has limited the growth of branded products. In addition, because intellectual property law is not enforced in India, there is a disincentive for large pharmaceutical companies to launch their products in the country.

Scope

  • Overview of Rheumatoid arthritis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in the India including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in the India from 2013-2023.
  • Analysis of the impact of key events as well the drivers and restraints affecting the India Rheumatoid arthritis market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid arthritis
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2013-2023 in the India

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms
  • 3.3. Prognosis
  • 3.4. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines
    • 4.1.3. Leading Prescribed Drugs for the Treatment of RA
    • 4.1.4. Clinical Practice
  • 4.2. India

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Product Profiles - Major Brands
    • 5.2.1. Enbrel (etanercept)
    • 5.2.2. Remicade (infliximab)
    • 5.2.3. Orencia (abatacept)
    • 5.2.4. Actemra/RoActemra (tocilizumab)
    • 5.2.5. Rituxan/MabThera (rituximab)
    • 5.2.6. Inflectra/Remsima (infliximab biosimilar)
    • 5.2.7. Methotrexate (Numerous Brands)
  • 5.3. Biosimilars
    • 5.3.1. Introduction
    • 5.3.2. Hospira's Inflectra Versus J&J's Remicade in Key Autoimmune Diseases
    • 5.3.3. Biosimilars in the Immunology Community
    • 5.3.4. By the Numbers: Biosimilars in Development
    • 5.3.5. The Impact of Biosimilars Will be Felt Throughout the Pharmaceutical Industry
    • 5.3.6. Uptake of Biosimilars for RA is Expected to Vary by Market
  • 5.4. Other Therapies

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Development of Cost-Effective Therapies
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Biomarkers to Predict Responsiveness to Therapy
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Early Diagnosis of RA
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Personalized Treatment Approach
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development
    • 7.2.1. Sirukumab
    • 7.2.2. Cosentyx (secukinumab)
    • 7.2.3. Baricitinib
    • 7.2.4. RAVAX
  • 7.3. Other Drugs in Development

8. Market Outlook

  • 8.1. Drivers and Barriers - Global Issues
    • 8.1.1. Driver: Launch of novel drugs, including oral JAK inhibitors and novel biologics for RA
    • 8.1.2. Driver: Earlier diagnosis and treatment
    • 8.1.3. Driver: Market entry of biosimilars will bring a therapy option for those who cannot afford branded biologics
    • 8.1.4. Driver: Aging population and increasing prevalent cases of RA
    • 8.1.5. Barrier: Efforts to reduce costs in the treatment of RA
    • 8.1.6. Barrier: Lack of regulatory guidelines for biosimilars will delay their availability in some regions
    • 8.1.7. Barrier: Entry of biosimilars will create a less expensive treatment alternative
  • 8.2. India
    • 8.2.1. Forecast
    • 8.2.2. Key Events
    • 8.2.3. Drivers and Barriers - India

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed RA Patients
    • 9.4.2. Percentage of Drug-Treated Patients
    • 9.4.3. Drugs Included in Each Therapeutic Class
    • 9.4.4. Launch and Patent Expiry Dates
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Individual Drug Assumptions
    • 9.4.7. Generic and Biosimilar Erosion
    • 9.4.8. Pricing of Pipeline Agents
  • 9.5. Primary Research - KOLs Interviewed for This Report
  • 9.6. Primary Research - Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Analyst
    • 9.7.2. Reviewer
    • 9.7.3. Therapy Area Director
    • 9.7.4. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: Symptoms of RA
  • Table 2: 1987 ACR Diagnostic Criteria for RA
  • Table 3: 2010 ACR/EULAR Diagnostic Criteria for RA
  • Table 4: Treatment Guidelines for RA Used in India
  • Table 5: ACR 2012 Criteria for RA Remission and Low/Moderate/High Disease Activity
  • Table 6: EULAR 2013 Criteria for RA Remission
  • Table 7: Most Prescribed Biologics for RA (After csDMARDs) in the Indian Market, 2014
  • Table 8: RA Treatment Country Profile - India
  • Table 9: Leading Branded Treatments for RA 2014
  • Table 10: Product Profile - Enbrel
  • Table 11: 10-Year, Open-Label Safety and Efficacy Trial of Enbrel: Efficacy Results at 11 Years for Completers
  • Table 12: 10-year, Open-Label Safety and Efficacy Trial of Enbrel: Overall Safety Results
  • Table 13: Enbrel SWOT Analysis, 2014
  • Table 14: Product Profile - Remicade
  • Table 15: Remicade SWOT Analysis, 2014
  • Table 16: Product Profile - Orencia
  • Table 17: Orencia SWOT Analysis, 2014
  • Table 18: Product Profile - Actemra
  • Table 19: Actemra SWOT Analysis, 2014
  • Table 20: Product Profile - Rituxan
  • Table 21: Rituxan SWOT Analysis, 2014
  • Table 22: Product Profile - Inflectra/Remsima
  • Table 23: Inflectra/Remsima SWOT Analysis, 2014
  • Table 24: Product Profile - MTX
  • Table 25: MTX SWOT Analysis, 2014
  • Table 26: Biosimilars Pipeline for RA, 2013
  • Table 27: Physician Uptake of Biosimilar Products for RA in India, 2014
  • Table 28: Summary of Minor Therapeutic Drug Classes Used to Treat RA, 2014
  • Table 29: Unmet Need and Opportunity in RA, 2014
  • Table 30: Comparison of Therapeutic Drug Classes in Development for RA, 2014
  • Table 31: Product Profile - Sirukumab
  • Table 32: Sirukumab SWOT Analysis, 2014
  • Table 33: Product Profile - Cosentyx
  • Table 34: Cosentyx SWOT Analysis, 2014
  • Table 35: Product Profile - Baricitinib
  • Table 36: Baricitinib Phase IIb Trial, Part A: ACR Responses at Week 12
  • Table 37: Baricitinib Phase IIb Trial, Part B: ACR Responses at Weeks 24 and 52
  • Table 38: Baricitinib Phase IIb Trial, Part A: Safety at Week 12
  • Table 39: Baricitinib Phase IIb Trial, Part A, Laboratory Values at Week 12
  • Table 40: Baricitinib SWOT Analysis, 2014
  • Table 41: Product Profile - RAVAX
  • Table 42: RAVAX SWOT Analysis, 2014
  • Table 43: Drugs in Phase II of Development for RA, 2014
  • Table 44: Global RA Market - Drivers and Barriers, 2013-2023
  • Table 45: Sales Forecasts ($m) for RA in India, 2013-2023
  • Table 46: Key Events Impacting Sales for RA in India, 2013-2023
  • Table 47: RA Market in India - Drivers and Barriers, 2013-2023
  • Table 48: Key Launch Dates of RA Products in India
  • Table 49: Key Patent Expiries
  • Table 50: High-Prescribing Physicians (non-KOLs) Surveyed in India

List of Figures

  • Figure 1: Normal Synovial Joint and Synovial Joint with RA
  • Figure 2: Cellular and Cytokine Targets for the Current RA Drugs
  • Figure 3: Disease Management Flowchart for Early RA - ACR 2012
  • Figure 4: Disease Management Flowchart for Established RA - ACR 2012
  • Figure 5: Flowchart for the Management of RA - EULAR 2013
  • Figure 6: Biosimilar Prescribing Habits in RA Across the 10MM, 2014
  • Figure 7: RA - Phase II-III Pipeline, 2014
  • Figure 8: Competitive Assessment of Late-Stage Pipeline Agents in RA, 2013-2023
  • Figure 9: Clinical and Commercial Positioning of Sirukumab
  • Figure 10: Clinical and Commercial Positioning of Cosentyx
  • Figure 11: Clinical and Commercial Positioning of Baricitinib
  • Figure 12: Clinical and Commercial Positioning of RAVAX
  • Figure 13: Sales for RA in India by Drug Class, 2013-2023
Back to Top